1.0700
08-10月-24 09:57:20
15 分の遅延
株式
0.0000
0.00%
本日の幅
1.0700 - 1.1100
ISIN
N/A
ソース
NASDAQ
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
09 12 2021 11:05:00 提供 Nasdaq GlobeNewswire
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
06 12 2021 08:00:04 提供 Nasdaq GlobeNewswire
IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
09 11 2021 11:06:22 提供 Nasdaq GlobeNewswire